Right time to take profit off the table in pharma; defence a structural buy: Rajiv Batra

Rajiv Batra addresses global investors' concerns about India's growth and policy, emphasizing the need for double-digit earnings and nominal GDP growth to reignite foreign investor interest. He suggests profit-taking in pharma due to US generic concerns and underwhelming earnings. Batra remains positive on financials and monitors the Jackson Hole Symposium for its impact on rate cuts.